Cristiano Fava

Prof. Cristiano Fava

Department of Clinical Sciences, Lund University, University Hospital of Malmö, Sweden; Department of Medicine, University of Verona, Azienda Ospedaliera Universitaria Integrata di Verona, General Medicine & Hypertension Unit, Hospital “Policlinico G.B. Rossi”, P.le L.A. Scuro 10, 37134 Verona, Italy

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 November 2012 in Clinical Pharmacology & Therapeutics
Verified
Journal Article
Closed access
PDF file
Elisa DaneseElisa Danese
Elisa Danese
MMM Montagnana
M Montagnana
JJJ A Johnson
J A Johnson
ARA E Rettie
A E Rettie
CZC F Zambon
C F Zambon
CFCristiano Fava
Cristiano Fava

3 October 2007 in Human Molecular Genetics
Verified
Journal Article
Open access
PDF file
CFCristiano Fava
Cristiano Fava
MMM. Montagnana
M. Montagnana
LRL. Rosberg
L. Rosberg
PBP. Burri
P. Burri
PAP. Almgren
P. Almgren
OMO. Melander
O. Melander
Gitelmańs syndrome (GS) is an inherited recessive disorder caused by homozygous or compound heterozygous loss of function mutations of the NaCl cotransporter (NCCT) gene encoding the kidney-expressed NCCT, the pharmacological target of thiazide diuretics. An observational study estimated the prevalence of GS to 19/1 000 000, in Sweden, suggesting that ∼1% of the population carries one mutant NCCT allele. As the phenotype of GS patients, who always carry two mutant alleles, is indistinguishable from that seen in patients treated with high-dose thiazide diuretics, we aimed at investigating whether subjects carrying one mutated NCCT allele have a phenotype resembling that of treatment with low-dose thiazide diuretics. We screened first-degree relatives of 18 of our patients with an established clinical end genetic diagnosis of GS for NCCT loss of function mutations and identified 35 healthy subjects carrying one mutant allele (GS-heterozygotes). Each GS-heterozygote was assigned a healthy control subject matched for age, BMI and sex. GS-heterozygotes had markedly lower blood pressure (systolic 103.3 ± 16.4 versus 123.2 ± 19.4 mmHg; diastolic 62.5 ± 10.5 versus 73.1 ± 9.4 mmHg; P < 0.001) than controls. There was no significant difference between the groups either in plasma concentration or urinary excretion rate of electrolytes, however, GS-heterozygotes had higher fasting plasma glucose concentration. Similar to patients being treated with low-dose thiazide diuretics, GS-heterozygotes have markedly lower blood pressure and slightly higher fasting plasma glucose compared with control subjects. Our findings suggest that GS-heterozygotes, the prevalence of which can be estimated to 1%, are partially protected from hypertension through partial genetic loss of function of the NCCT. However, as our study had a case–control design, it is important to underline that any potential effects on population blood pressure and risk of future cardiovascular disease need to be examined in prospective and population-based studies.

1 January 2006
Verified
Journal Article
Closed access
PMPietro Minuz
Pietro Minuz
CFCristiano Fava
Cristiano Fava
ALAlessandro Lechi
Alessandro Lechi

3 January 2008 in Journal of Human Hypertension
Verified
Journal Article
Open access
PDF file
CFCristiano Fava
Cristiano Fava
MRM S Ricci
M S Ricci
PBP Burri
P Burri
PMP Minuz
P Minuz
OMO Melander
O Melander
Heritability of the ambulatory arterial stiffness index in Swedish families